Latest Packaging News

Prescient Therapeutics has reached the first planned review threshold in its PTX-100 Phase 2a lymphoma study, while a completed A$6.0 million raise extends funding beyond the December milestone. The review will assess safety and efficacy, but is not a study completion or a new clinical result.

The US FDA has supported six of seven elements NeuroScientific Biopharmaceuticals put forward for its planned StemSmart Phase 2 Crohn’s disease trial. The remaining issue is a manufacturing control for viral contamination, while trial commencement remains targeted for the end of 2026 and subject to further requirements.

WiseTech Global’s FY26 annual report charts a year of extraordinary expansion, with revenue up 79% after the e2open acquisition and underlying EBITDA up 56%. But the stronger earnings base comes with heavier debt, a major workforce reset and unresolved regulatory risks.

EDU Holdings has lifted total enrolments 26% to a record 7,489, with Higher Education up 45% and now accounting for 88% of the group. The result also exposes a sharper divide: domestic and postgraduate demand is strengthening, while international VET enrolments continue to contract.

Ionic Rare Earths has moved its Belfast magnet recycling project closer to construction while expanding into the United States through a proposed US$100 million joint venture. The progress comes with key funding, approvals and definitive agreements still outstanding.

Ore Resources has added 408.87 square kilometres to its Kal East gold footprint in Western Australia, but all 18 new tenements remain pending. The company plans to begin 3,000-5,000 metres of aircore drilling at Mt Monger in November, subject to heritage clearances.

Nyrada has received supportive written feedback from the US FDA on its proposed pathway for taking Xolatryp into a US Phase IIa heart-attack trial. The regulator identified no major issues, but additional information and stability data are still required before the planned IND submission in the first half of 2027.

Pengana International Equities has declared a 1.4 cents per share fully franked quarterly dividend, with payment scheduled for 15 December. The distribution implies a 4.93% annualised yield at the company’s 9 October share price, assuming the quarterly rate continues.

BOA Resources has reported further high-grade copper intersections at Ricci Lee, strengthening evidence of a continuous mineralised system rather than isolated historical hits. Assays from 12 more RC holes and five other Neds Creek prospects could now shape the path towards a maiden Mineral Resource.

Glencore has confirmed its binding offtake agreement for Centaurus Metals’ Jaguar Nickel Project remains effective, preserving a key commercial pillar as the developer negotiates the rest of its funding package. No new funding commitment or Final Investment Decision has yet been announced.

Acrux says the FDA has confirmed the evidence package required to take its female testosterone spray into Phase III trials for postmenopausal women with HSDD. The agency also indicated the company may apply for three years of data exclusivity if the product reaches submission.

Nyrada has lodged a prospectus for approximately 10.74 million free options linked to its recent capital raising, giving eligible CDI holders three options for every four CDIs issued. The options carry a $0.93 exercise price and could generate almost $10 million if fully exercised, although that cash remains contingent on holder participation.